<DOC>
	<DOCNO>NCT02728102</DOCNO>
	<brief_summary>The study design Phase II , multicenter trial vaccination Dendritic cell/myeloma fusion granulocyte macrophage colony-stimulating factor ( GM-CSF ) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone GM-CSF follow autologous transplant part upfront treatment multiple myeloma ( MM ) . It hypothesize dendritic cell myeloma vaccine result improve response patient multiple myeloma autologous Hematopoietic Cell Transplant ( HCT ) .</brief_summary>
	<brief_title>Dendritic Cell/Myeloma Fusion Vaccine Multiple Myeloma ( BMT CTN 1401 )</brief_title>
	<detailed_description>The study three-arm , phase II randomize , open-labeled clinical trial randomize patient vaccination Dendritic Cell ( DC ) /myeloma fusions/GM-CSF plus lenalidomide maintenance therapy lenalidomide maintenance therapy without GM-CSF follow autologous transplant part upfront treatment patient diagnose multiple myeloma . Patients randomize day 60 +/- 7 day post transplant begin maintenance lenalidomide day 90 100 . The primary objective randomize trial compare proportion patient alive complete response ( define CR sCR ) one year post transplant patient receive DC/myeloma vaccine/GM-CSF lenalidomide maintenance therapy receive lenalidomide maintenance therapy without GM-CSF .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Initial 1 . Patients must consider transplant eligible treat physician time study entry . 2 . Patients must meet criterion symptomatic multiple myeloma prior initiate systemic antimyeloma treatment . 3 . Age &gt; 18 year ≤ 70 year time enrollment 4 . Karnofsky Performance status ≥ 70 % 5 . Patients must &gt; 20 % plasma cell bone marrow aspirate differential &lt; 60 day prior enrollment . The required bone marrow evaluation need repeat patient receive 1 cycle antimyeloma therapy ( corticosteroid without antimyeloma agent ) 6 . Patients must receive &lt; 2 cycle systemic antimyeloma therapy . 7 . Renal : Creatinine clearance ≥ 40 mL/min , estimate calculate . Initial 1 . Patients prior autologous allogeneic HCT 2 . Patients purely nonsecretory MM [ absence monoclonal protein ( M protein ) serum measure electrophoresis immunofixation absence Bence Jones protein urine define use conventional electrophoresis immunofixation technique absence involve serum free light chain &gt; 100 mg/L ] . Patients light chain MM detect serum free light chain assay eligible . 3 . Patients Plasma Cell Leukemia 4 . Patients HighRisk Multiple Myeloma . Highrisk define presence one following : deletion chromosome 13 conventional cytogenetics , hypodiploidy , abnormality chromosome 1 ( 1q amplification 1p deletion ) , ( 4 ; 14 ) , ( 14 ; 16 ) , ( 14 ; 20 ) deletion 17p fluorescence situ hybridization ( FISH ) conventional karyotyping ; highrisk criterion base commercially available gene expression profile ( GEP ) detect time prior enrollment ; 5 . Patients disease progression prior enrollment 6 . Patients seropositive human immunodeficiency virus ( HIV ) . 7 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . 8 . Patients active clinically significant autoimmune disease , define history require systemic immunosuppressive therapy ongoing risk potential disease exacerbation . Patients history autoimmune thyroid disease , asthma , limited skin manifestation potentially eligible . 9 . Patients receive investigational immunotherapy antimyeloma drug within 14 day enrollment . 10 . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &lt; 5 year prior enrollment allow unless approve Protocol Officer one Protocol Chairs . Cancer treat curative intent &gt; 5 year prior enrollment allow . 11 . Female patient pregnant ( positive betaHCG ) breastfeeding . 12 . Females childbearing potential ( FCBP ) men sexual contact FCBP unwilling use contraceptive technique ( Appendix D ) length lenalidomide maintenance therapy . 13 . Patients receive midintensity melphalan ( &gt; 50 mg IV ) part prior therapy . 14 . Prior organ transplant require immunosuppressive therapy . 15 . Patients previously receive lenalidomide experienced toxicity result treatment discontinuation . 16 . Patients experience thromboembolic event full anticoagulation prior therapy lenalidomide thalidomide . 17 . Patients unwilling take deep vein thrombosis ( DVT ) prophylaxis . 18 . Patients unable unwilling provide inform consent . 19 . Patients unable unwilling return transplant center assign treatment . Randomization 1 . Patient receive transplant &lt; 12 month enrollment onto BMT CTN 1401 . 2 . No disease progression since initiation systemic antimyeloma therapy determine within seven day randomization/enrollment . 3 . Received autologous cell transplant melphalan 200mg/m^2 minimum cell dose 2x10^6 CD34+ cells/kg ( actual body weight ) . 4 . Mucositis gastrointestinal symptom resolve , hyperalimentation intravenous hydration . 5 . No evidence uncontrolled infection require systemic therapy . Patients complete treatment infection continue antibiotic , antiviral , antifungal therapy prophylaxis eligible continue protocol . 6 . Platelet count ≥75,000/mm^3 ( without transfusion previous 7 day ) . 7 . Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 without filgrastim administration within 7 day , pegfilgrastim within 14 day measurement . 8 . Hepatic : bilirubin &lt; 2x upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5x upper limit normal . ( Patients diagnose Gilbert 's Disease allow exceed define bilirubin value 2x upper limit normal ) 9 . Renal : Creatinine clearance ≥ 40 mL/min , estimate calculated . Patients creatinine clearance ≥30 &lt; 40 consider review/approval protocol chair officer cause renal insufficiency associate multiple myeloma . 10 . All study participant must register mandatory Revlimid REMs program , willing able comply requirement . 11 . Females childbearing potential ( FCBP ) define section 2.7.1.1 must negative serum pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) 12 . FCBP must either commit abstain continuously sexual intercourse use TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide , therapy , dose interruption , continue 4 week follow discontinuation lenalidomide . 13 . FCBP must agree ongoing pregnancy test require Revlimid REMs program . 14 . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy take lenalidomide , dose interruption 28 day discontinue lenalidomide . 15 . Patients must willing receive DVT prophylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Hematologic Disorders</keyword>
	<keyword>Vaccine</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Transplant</keyword>
	<keyword>Anti-Myeloma Agents</keyword>
</DOC>